How do I interpret a whole-body PET-CT scan?

How to Interpret a Whole-Body PET-CT Scan

Interpret whole-body PET-CT scans using a systematic approach that integrates both metabolic (PET) and anatomic (CT) findings, beginning with assessment of study quality, followed by identification of pathological FDG uptake patterns compared to normal tissue, and concluding with correlation of metabolic abnormalities to anatomic structures. 1

Systematic Review Sequence

1. Initial Quality Assessment

Before interpreting findings, evaluate technical quality factors that may limit diagnostic accuracy 1:

• Motion artifacts that degrade image quality 1
• Abnormal tracer biodistribution including FDG accumulation in muscles or brown fat 1
• Tracer infiltration at the injection site 1
• Hyperglycemia at time of injection (blood glucose should be documented) 1
• CT-related artifacts such as metallic implants or beam hardening 1
• Patient body habitus effects on image quality 1

2. Display and Threshold Settings

Proper image display is essential for accurate interpretation 2:

• Adjust intensity thresholds appropriately to visualize both high and low-grade uptake 2
• Review multiple image planes (axial, coronal, sagittal) systematically 2
• Use standardized uptake values (SUV) for semiquantitative assessment 1

3. Identify Pathological FDG Uptake

Describe abnormal metabolic activity by 1:

• Location and extent of FDG accumulation 1
• Intensity measurement using SUV and/or SUL (SUV lean body mass) 1
• Comparison to background uptake in normal tissues, particularly liver parenchyma (mean SUV 2.0-3.0, maximum SUV 3.0-4.0) 1
• Characterization as mild, moderate, or intense relative to liver uptake 1

4. Correlate PET Findings with CT Anatomy

Integration of metabolic and anatomic data is critical 2, 3, 4:

• Match areas of increased FDG uptake to specific anatomic structures on CT 2, 3
• Describe all relevant CT findings, including those that are FDG PET-negative 1
• Identify the relationship between metabolic abnormalities and anatomic lesions 1
• Recognize that PET and CT must be interpreted together to optimize diagnostic accuracy, as either study alone is prone to errors 4

5. Recognize Physiological Variants and Pitfalls

Common causes of false-positive interpretations include 5, 6:

• Physiological FDG uptake in kidneys, bladder, skeletal muscle, myocardium, and brown fat 5
• Inflammatory conditions that mimic malignancy 1, 5, 6
• Muscle activity from recent exercise or tension 1, 5
• Benign lesions with high glycolytic activity 2, 5

Common causes of false-negative interpretations include 1, 6:

• Small lesions affected by partial volume effect 1
• Malignancies with low metabolic activity that may not be FDG-avid 2, 6
• High blood glucose levels reducing tumor-to-background contrast 1

6. Compare with Prior Studies

Serial comparison is essential for therapy assessment 1:

• Document changes in extent and intensity of FDG uptake 1
• Use both visual and semiquantitative assessment (absolute or relative SUV changes) 1
• Apply standardized response criteria such as PERCIST for solid tumors or five-point scale for lymphomas 1
• Ensure comparable protocols between studies for reliable comparison 1

7. Address the Clinical Question

Structure your interpretation to directly answer the referring physician's question 1:

• Clearly identify the study as normal or abnormal 1
• Provide definite diagnosis when possible, including staging assessment (TNM or other) 1
• State differential diagnoses with qualitative likelihood estimates when diagnosis is uncertain 1
• Include incidental findings of clinical relevance 1
• Recommend additional studies or biopsy when appropriate 1

Critical Pitfalls to Avoid

• Do not interpret PET without CT correlation or vice versa, as this significantly increases diagnostic errors 4
• Do not overlook CT-based attenuation correction artifacts that can create false-positive PET findings 5
• Do not assume all FDG uptake is malignant—always consider inflammatory and physiological causes 5, 6
• Do not ignore confounding factors such as recent chemotherapy, radiation, or surgery that alter FDG distribution 1